| Dr Adam Wesley Nachand, PHARMD | |
|
9800 Lyndale Ave S, Bloomington, MN 55420-4731 | |
| (952) 884-8246 | |
| Not Available |
| Full Name | Dr Adam Wesley Nachand |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 9800 Lyndale Ave S, Bloomington, Minnesota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205111374 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 117220 (Minnesota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Adam Wesley Nachand, PHARMD 9800 Lyndale Ave S, Bloomington, MN 55420-4731 Ph: (952) 884-8246 | Dr Adam Wesley Nachand, PHARMD 9800 Lyndale Ave S, Bloomington, MN 55420-4731 Ph: (952) 884-8246 |
News Archive
It used to be a fear of the dentist that kept us away from the dental chair but today it is more than twice as likely to be the cost of dental care that's holding us back, according to research from Tesco Dental Insurance.
Decades of declines in LDL cholesterol blood levels, a key marker of death risk from heart disease, abruptly ended in 2008, and may have stalled since, according to a multi-year, national study published in PLOS ONE.
Although hip fractures in older patients are known to be a major cause of long term disability and increased risk of death, less is known about the relationship between surgical delay after hip fracture and mortality risk.
The first study to investigate risk factors for the vascular condition called CCSVI (chronic cerebrospinal venous insufficiency) in volunteers without neurological disease has identified what the researchers call a remarkable similarity between this condition and possible or confirmed risk factors for multiple sclerosis.
Silence Therapeutics plc announces the issuance of United States patent 7,750,144, titled Methods and Compositions for Enhancing Efficacy and Specificity of RNA Silencing, by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of producing double stranded (RNAi) agents having decreased off-target silencing activity through certain structural modifications. The ability to minimize the off-target effects of RNAi therapeutics is critical for controlling unwanted cellular activity and/or potential safety concerns.
› Verified 8 days ago
Timothy Casey, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7845 Portland Ave S, Bloomington, MN 55420 Phone: 952-881-1253 Fax: 952-881-2656 | |
Dr. Phillip Rasmussen, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9800 Lyndale Ave S, Bloomington, MN 55420 Phone: 952-884-8246 | |
Dr. Leann C Mcdowell, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 8170 33rd Ave S, Bloomington, MN 55425 Phone: 952-967-6952 | |
Dr. Youssef Roman, PHARM.D., PH.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 8170 33rd Ave S, Bloomington, MN 55425 Phone: 952-883-6000 | |
Jacqueline Larson, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 10501 Florida Ave S, Bloomington, MN 55438 Phone: 952-854-1190 | |
Melissa Salmela, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9800 Lyndale Ave S, Bloomington, MN 55420 Phone: 952-884-8246 | |
Dr. Patty Ann Doyle, PHARM.D., BCGP Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 8712 Sandro Rd, Bloomington, MN 55438 Phone: 612-396-4974 Fax: 612-396-4974 |